Indication
Mixed Lineage Acute Leukemia
3 clinical trials
7 products
Product
SNDX-5613Product
cobicistatClinical trial
A Phase 1/2, Open-label, Dose-Escalation and Dose-Expansion Cohort Study of SNDX-5613 in Patients With Relapsed/Refractory Leukemias, Including Those Harboring an MLL/KMT2A Gene Rearrangement or Nucleophosmin 1 (NPM1) MutationStatus: Recruiting, Estimated PCD: 2024-12-01
Product
ZiftomenibClinical trial
A Phase 1/2 First in Human Study of the Menin-MLL(KMT2A) Inhibitor KO-539 in Patients With Relapsed or Refractory Acute Myeloid LeukemiaStatus: Recruiting, Estimated PCD: 2024-09-30
Clinical trial
Phase 1 Study of Venetoclax/Azacitidine or Venetoclax in Combination With Ziftomenib or Standard Induction Cytarabine/Daunorubicin (7+3) Chemotherapy in Combination With Ziftomenib for the Treatment of Patients With Acute Myeloid LeukemiaStatus: Recruiting, Estimated PCD: 2026-05-01
Product
VenetoclaxProduct
DaunorubicinProduct
AzacitidineProduct
Cytarabine